JBJeromie Ballreich

Jeromie Ballreich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeromie Ballreich has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025

    by Yunxiang Sun, Jeromie Ballreich, Joy Acha, Riya Modi, Mohammad Ali Alamdar Yazdi, Maqbool Dada, Tinglong Dai, Gerard Anderson, Mariana P Socal

    Background: The U.S. Food and Drug Administration (FDA) inspections are central to oversight of the pharmaceutical manufacturing base, but long-term inspection and reinspection patterns remain incompletely characterized. Methods: We analyzed 25 629 FDA Drug Quality Assurance inspections conducted from October 2008 through December 2025. We described annual, regional, and outcome patterns. Linking inspections to facilities, we examined time to reinspection according to the outcome of preceding inspections. Results: Annual Drug Quality Assurance inspections declined from 1594 in 2019 to 461 in 2020 and increased to 1218 in 2025. The United States remained the largest single region of inspection activity, but its contribution declined over time. The proportion of favorable inspection outcomes (no action indicated—NAI) decreased from 40.0% before the pandemic to 19.3% during and 23.7% after. Unfavorable outcomes (voluntary action indicated—VAI—and official action indicated—OAI) increased accordingly. The mean reinspection interval was 3.18 years after NAI, 2.96 after VAI, and 2.12 after OAI (P < .001). Median times were 4.08, 3.51, and 3.02 years, respectively. Conclusion: FDA inspection activity had not returned to prepandemic levels by 2025. Unfavorable inspection outcomes were associated with earlier reinspection, consistent with risk-responsive oversight. However, the available data cannot establish whether follow-up was timely or adequate.

  • Open Access

    Healthcare Cost Impacts of Telehealth-Delivered Nutrition Therapy among US Adults with Type 2 Diabetes or Obesity: A Matched Difference-in-Differences Analysis

    by Priya V. Shanmugam, Rebecca N. Adams, Shaminie J. Athinarayanan, Adam J. Wolfberg, Jeromie M. Ballreich

  • Medicaid access to Most Favored Nation through the Pfizer agreement: The unanswered issues

    by Jeromie Ballreich, Joseph Levy, Tucker Desmond, Nathan Jibat, Gerard Anderson

    In the following commentary, we discuss the motivation for the Trump-Pfizer Most Favored Nation (MFN) pricing deal, a preliminary analysis on potential savings, and discussion on the details that will determine the success of the Trump-Pfizer deal. This deal represents the Trump administration's pursued health policy to get Americans a "better deal" for drug pricing by providing Medicaid programs access to MFN pricing for Pfizer-branded drugs. Using different data sources, we provide a preliminary analysis on the deal's impact on 6 Pfizer drugs. Our results suggest Medicaid programs may save a maximum of $280 million from access to MFN pricing, reflecting 11.5% in additional rebates off gross spending. Medicaid programs will have greater potential net savings when using MFN benchmarking for newer drugs with lower baseline rebates compared with older, highly rebated drugs. It is uncertain if the MFN prices will apply to all new and existing Pfizer drugs or just a selection. We also highlight several implementation challenges ranging from different marketed names of drugs to selection of countries for MFN pricing that will influence the deal's impact.

  • Open Access

    Systematic review of economic evaluations of curative treatments for sickle cell disease

    by Ijele Adimora, Bethel Abraham, Sanya Joshi, Robert Brodsky, Katie Lobner, Jeromie Ballreich

    Sickle cell disease (SCD) leads to high rates of morbidity, early mortality, and high healthcare costs. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and gene therapy represent curative approaches for SCD, however, both approaches come with risks of treatment-related toxicities, financial toxicities, and risk of mortality. Cost-effectiveness studies evaluate the financial impact of disease interventions against the gains to quality of life achieved by an intervention. Given the multiple curative interventions in SCD, including myeloablative matched-related and non-myeloablative haploidentical allogeneic transplantation as well as the novel gene therapies, the objective of this review is to summarize the methods and results of published cost-effectiveness studies of curative therapies for SCD. We analyzed economic evaluation approaches for assessing the cost-effectiveness of curative modalities in SCD including model approaches, cost input sources, health state utility values, economic perspectives, time horizons, and cost-effectiveness outcomes. We found significant heterogeneity across all assessed aspects for cost-effectiveness of curative interventions in SCD. One common theme was that most studies reported cost-effectiveness results of curative interventions at high incremental cost-effectiveness ratios, suggesting curative interventions may offer a weak value proposition to the healthcare system when compared to accepted willingness- to-pay thresholds. The value proposition is improved, particularly for gene therapies, when assessed using a societal perspective. Most analyses compared only one curative modality to standard of care suggesting a need for assessing the value across curative modalities.

  • Open Access

    Potential impact of tariffs on active pharmaceutical ingredients on the price of US-made generic drugs

    by Mariana P Socal, Yunxiang Sun, Jeromie Ballreich, Joy Acha, Mohammad Ali Yazdi, Tinglong Dai, Maqbool Dada

    Introduction: The impact of tariffs on prescription drug prices has been poorly understood. Methods: Using US importation data 2019-2024, this study modeled the potential impact of tariffs on the prices of generic drugs manufactured in the United States with imported active pharmaceutical ingredients (APIs). Results: Under baseline assumptions a 100% worldwide tariff would result in average price increase of 30% (additional $21.15 per prescription) and a blended tariff based on rates proposed by the Federal Administration would result in an average price increase of 10% (additional $6.22 per prescription) for domestically produced generics using imported APIs. Estimates varied across drugs reflecting different API importation patterns. Assumptions on the tariff rate, the contribution of the API cost to the final drug price, and on the supply chain's ability to absorb the added tariff contributed markedly to determining the final price. The study findings do not generalize to US-made generics using US-made APIs but could be relevant to US-made branded drugs using imported APIs. Conclusion: Tariffs could raise costs for US drug manufacturers using imported APIs, potentially limiting affordability and manufacturers’ competitiveness in United States and global markets. Policies to incentivize “made-in-America” prescription drugs should incentivize domestic API production or reconsider API tariffs.


  • Open Access

    Impact of telehealth nutrition therapy on costs and utilization in type 2 diabetes & obesity

    by Priya V. Shanmugam, Rebecca N. Adams, Shaminie J. Athinarayanan, Adam J. Wolfberg, Jeromie Ballreich

    Structured Importance: Type 2 diabetes and obesity drive substantial morbidity and spending. Rigorous evidence on the impacts of digitally delivered lifestyle interventions on healthcare cost and utilization are critical to assessing their value. Objective: Determine the impact of a telehealth-delivered individualized nutrition therapy (INT) program on per-member-per-month (PMPM) total cost of care and utilization over one and two years. Design: Retrospective propensity score matched difference-in-differences analysis of cost and utilization outcomes over the study period of January 2016–March 2025. Setting: US adults participating in a telehealth T2D and obesity management program. Participants: Enrolled in INT for >1 day or had PCP visit for T2D or obesity during study period; had ≥12 months pre-index and ≥90 days post-index claims coverage (allowing ≤30-day gaps). Final matched sample: 6,580 participants and 6,580 controls (per arm: 3,819 with type 2 diabetes and 2,761 with obesity). Exposures: Telehealth-delivered, continuous care integrating individualized carbohydrate-reduced nutrition support, clinician-guided medication management, health coaching, and remote biometric monitoring. Main Outcomes and Measures: Outcomes included PMPM allowed inpatient, outpatient, and prescription medication costs, inpatient, emergency department, primary care, cardiology, and endocrinology visits. For the T2D cohort, PMPM spending and proportion of days covered for each T2D medication. Results: Among 3,819 adults with T2D and 2,761 adults with obesity, program participation was associated with $240 and $256 PMPM reductions in the total cost of care at 12 months (−$230 and $189 over 24 months, all P<.001). In the T2D cohort, savings were driven by deprescription of SGLT2 inhibitors (66.8% reduction in PMPM cost), sulfonylureas (51.7%), insulin (43.9%), and GLP-1s (32.2%). In the obesity cohort, reductions accrued across inpatient, outpatient and prescription medication settings. Conclusions and Relevance: In this large, real-world analysis, a nutrition-first digital care model was associated with sustained reductions in cost and utilization over 12–24 months, with immediate prescription medication cost reductions in the cohort with T2D and broader savings in the cohort with obesity. Together with prior clinical evidence, these findings suggest alignment of clinical effectiveness and cost reductions of a telehealth-delivered lifestyle intervention. Key points: Question: Is participation in a telehealth-delivered individualized nutrition therapy program associated with changes in healthcare costs and utilization among adults with type 2 diabetes (T2D) or obesity? Findings: In this retrospective cohort study of 13,000 matched adults, participation was associated with lower total cost of care at one year (−$240 and −$256 for adults with T2D and obesity respectively) and over two years (T2D: -$230; obesity: $-189). Among adults with T2D, reductions were driven by inpatient costs and all T2D medications, including GLP-1s. Among adults with obesity, reductions occurred across inpatient, outpatient, and prescription medication costs. Meaning: Telehealth-delivered nutrition therapy may reduce healthcare spending for adults with T2D or obesity.

  • Open Access

    Key Drivers and Mitigation Strategies of Oncology Drug Shortages 2023 to 2025

    by Mariana P. Socal, Joy Acha, Chia-Yu Yang, Yunxiang Sun, Maqbool Dada, Tinglong Dai, Gerard Anderson, Jeromie Ballreich

    Drug shortages remain a problem in the United States, jeopardizing patient care. To help inform solutions, this study reviewed recent oncology drug shortages for causes and mitigation strategies. Using the FDA’s Drug Shortage Database, 15 oncology drugs with shortages between 2023 and 2025 were identified. Twelve drugs had shortages lasting >2 years (maximum: >13 y). Searches of PubMed and Google Scholar, online media sources, and FDA documents uncovered 9 main causes: manufacturing quality problems, limited-source dependency, regulatory bottlenecks, global over-reliance, absence of buffer stocks, demand surges, low economic incentives, active pharmaceutical ingredient shortages, and shelf-life constraints. Mitigation strategies involved 4 stakeholders: regulators (expedited regulatory action, importation, expiration extensions), manufacturers (capacity expansion), providers (dose-sparing regimens, therapeutic alternative protocols, allocation prioritization), and purchasers-distributors including GPOs (supply collaboration). Policies to mitigate drug shortages should include new approaches to identify vulnerable markets and involve multiple stakeholders. Factors identified in this study also offer pathways for shortage prevention.


  • Open Access

    Research and development financing models for new biopharmaceuticals in the United States

    by So-Yeon Kang, Branden Lee, Ravi Gupta, Jeromie Ballreich, Gerard Anderson


  • Cost-Effectiveness Analysis of the Technology-Enhanced Community Health Nursing Program for Adolescent Girls and Young Adult Women With Pelvic Inflammatory Disease

    by Jeromie PhD Ballreich, K. Davina Frick, Steve Huettner, Jamie Perin, Charlotte DrPH Gaydos, Jennifer Anders, Richard Rothman, Maria Trent

    Background: Pelvic inflammatory disease (PID) disproportionately impacts adolescents and young adult women. The Technology-Enhanced Community Health Nursing (TECH-N) trial demonstrated the potential benefit of a novel community health intervention for adolescents with PID. We assess the cost-effectiveness of TECH-N compared with standard care. Methods: We constructed a cohort Markov model to assess the cost-effectiveness of TECH-N for adolescents with PID in an urban setting. The model used nine health states: PID; two states for STIs; four states for PID sequelae, recovery, and deceased states. The cohort consisted of 18-year-old female adolescents with mild to moderate PID. Transition probabilities were derived from the TECH-N clinical trial and published literature. Health state utilities were derived from published literature. Intervention costs were estimated using TECH-N data, and health state costs were derived from published literature and public databases. The model took a health system perspective over a 10-year time horizon. Sensitivity analyses were used to assess uncertainty. Cost-effectiveness was estimated using the discounted incremental cost-effectiveness ratio with effects measured in quality-adjusted life years (QALYs). Results: Over ten years, the TECH-N cohort generated 8.16 QALYs per individual at a cost of $20,419 compared with standard care with 8.14 QALYs costing $20,492. The resulting incremental cost-effectiveness ratio was negative since the intervention produced more QALYs at a lower cost; suggesting TECH-N is cost-saving. Conclusions: Our model suggests the TECH-N intervention yields better outcomes at lower overall costs. In addition, the nature of TECH-N lends itself to being coupled with other home-health/community strategies, which could further improve its value proposition.


  • SOCIODEMOGRAHIC AND SPENDING CHARACTERISTICS OF MEDICARE BENEFICIARIES TAKING PRESCRIPTION DRUGS SUBJECT TO PRICE NEGOTIATIONS

    by Ilina C. Odouard, Gerard Anderson, G. Caleb Alexander, Jeromie Ballreich

    BACKGROUND: The 2022 Inflation Reduction Act authorizes Medicare to negotiate the prices of 10 drugs in 2026 and additional drugs thereafter. Understanding the sociodemographic and spending characteristics of beneficiaries taking these specific drugs could be important describing the impact of the legislation. OBJECTIVE: To describe sociodemographic and spending characteristics of Medicare beneficiaries who use the 10 prescription drugs ("negotiated drugs") that will face Medicare drug price negotiations in 2026. METHODS: A 20% sample of Medicare Part D beneficiaries from 2020 (n = 10,224,642) was used. Sociodemographic and spending characteristics were descriptively reported for beneficiaries taking the negotiated drugs, including subgroups by low-income subsidy (LIS) status and by drug, and for Part D beneficiaries not taking negotiated drugs. RESULTS: Part D beneficiaries taking a negotiated drug compared with Part D beneficiaries not taking a negotiated drug overall had similar sociodemographic characteristics, more comorbidities (3.9 vs 2.2) and higher mean [median] Medicare ($33,882 [$18,251] vs $12,366 [$3,429]) and out-of-pocket (OOP) spending ($813 [$307] vs $441 [$160]). There was variation in characteristics by LIS status. The mean age was highest among non-LIS beneficiaries taking a negotiated drug compared with LIS beneficiaries taking a negotiated drug and beneficiaries not taking a negotiated drug (76.2 vs 69.9 vs 71.4). Among beneficiaries using negotiated drugs, a higher percentage of LIS beneficiaries compared with non-LIS was female (59.7% vs 48.0%), was Black (20.9% vs 6.6%), and resided in lower-income areas (39.1% vs 20.3%). Mean [median] annual Part D OOP spending for negotiated drugs was $115 [$59] for beneficiaries with LIS and $1,475 [$1,204] for beneficiaries without LIS. There were also differences depending on which negotiated drug was used. Drugs for cancer and blood clots had the highest proportions of White users, whereas type 2 diabetes and heart failure drugs had the highest proportions of Black users and beneficiaries residing in lower -income areas. Annual Part D OOP costs were lowest for sitagliptin (LIS: $104 [$60], non-LIS: $1,391 [$1,153]) and highest for ibrutinib (LIS: $649 [$649], non-LIS: $6,449 [$6,867]). Among non-LIS beneficiaries, 24% (22% to 76%) had more than $2,000 in OOP costs. CONCLUSIONS: Inflation Reduction Act OOP spending caps and LIS expansion will lower prescription drug costs for beneficiaries with OOP costs exceeding $2,000 who are mostly White and live in higher-income areas, insulin users who are disproportionately Black with multiple chronic conditions, and beneficiaries with low incomes. However, these provisions will not impact the 76% of non-LIS beneficiaries using negotiated drugs who have OOP costs that are still substantial but below $2,000. Negotiations could reduce OOP costs through reduced coinsurance payments for this group, which is older and has more chronic conditions compared with beneficiaries not taking negotiated drugs. Part D plan design, spending, and utilization changes should be monitored after negotiation to determine if further solutions are needed to lower OOP costs for this group.